TRPS1 function beyond breast: A retrospective immunohistochemical study on non‐breast cytology specimens
- 25 May 2024
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (9) , 499-504
Abstract
Introduction: Trichorhinophalangeal syndrome type 1 (TRPS1) has emerged as a reliable immunohistochemistry (IHC) marker for identifying breast origin in metastatic carcinomas. This study investigates the utility of TRPS1 IHC in non‐breast cytology specimens.Materials and Methods: A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow‐up confirming non‐breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work‐up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.Results: Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.Conclusions: Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.Keywords
This publication has 13 references indexed in Scilit:
- TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?Human Pathology, 2023
- The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimensCancer Cytopathology, 2022
- Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimensJournal of the American Society of Cytopathology, 2022
- Evaluation of TRPS1 Expression in Pleural Effusion Cytology Specimens With Metastatic Breast CarcinomaAmerican Journal of Clinical Pathology, 2022
- Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and RevisitSeminars in Diagnostic Pathology, 2022
- PAX8 Expression in Breast CancerApplied Immunohistochemistry & Molecular Morphology, 2020
- Cytologic evaluation of p16 staining in head and neck squamous cell carcinoma in CytoLyt versus formalin‐fixed materialCancer Cytopathology, 2019
- CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki‐67 clone 30‐9 is not susceptible to the inhibition: Critical diagnostic implicationsCancer Cytopathology, 2019
- GATA3 expression in triple‐negative breast cancersHistopathology, 2017
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010